ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

153 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-14

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).

The main questions the study aims to answer are:

* Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
* What adverse events do participants have when taking ACP-211?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

NCT01098240

Major Depressive Disorder

TERMINATED PHASE2

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT06785012

Depressive Disorder, Major

RECRUITING PHASE2

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT04985942

Major Depressive Disorder

COMPLETED PHASE3

Org 24448 to Treat Major Depression

NCT00113022

Depression

TERMINATED PHASE2

Adjunct Minocyline in Treatment-resistant Depression

NCT02456948

Major Depressive Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder (MDD) Depressive Disorder, Treatment-Resistant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACP-211 600 mg

ACP-211 600 mg, administered orally twice weekly

Group Type EXPERIMENTAL

ACP-211

Intervention Type DRUG

ACP-211 monotherapy

ACP-211 300 mg

ACP-211 300 mg, administered orally twice weekly

Group Type EXPERIMENTAL

ACP-211

Intervention Type DRUG

ACP-211 monotherapy

Placebo

Matching placebo, administered orally twice weekly

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Placebo control

Intervention Type DRUG

ACP-211

ACP-211 monotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥18 and ≤65 years of age at Screening
* Clinical diagnosis of MDD per DSM-5, confirmed by the MINI during Screening
* Willing to abstain from prohibited drugs or substances from Screening through the end of the study. Benzodiazepines, non-benzodiazepine sleep aids, and benztropine are prohibited from 12 hours before, until 24 hours after, each study drug administration.
* Willing to abstain from alcohol within 24 hours before and after study drug administration
* If female, the participant must either:

* Be of non-childbearing potential (defined as either at least 6 months surgically sterilized or at least 1 year postmenopausal), OR
* Have a male partner who has had a vasectomy, OR
* Beginning at least 28 days prior to the first dose of study drug until 28 days after the last dose, use a combination of two nonhormonal methods of contraception, such as:

* An IUD and a barrier method (e.g., condom, diaphragm) plus spermicide,
* Or a barrier method with her male partner using a condom.
* Females must have a negative serum hCG pregnancy test at Screening and a negative urine pregnancy test at Baseline.
* If male, the participant must:

* Use a condom (even if vasectomized) from Screening until 90 days after the last dose.
* Agree to not donate sperm for the duration of the study and until 90 days after the last dose.
* Inadequate response to ≥2 antidepressants (excluding MAOIs) with ≥1 inadequate response to antidepressant confirmed in the current episode of depression

* Includes patients who have had a partial response to antidepressants and those who have minimal or no response
* MGH ATRQ will be used to assess ADT response during the current episode
* Prior medication history will be used to determine ADT response in prior episode(s)
* Treated during the current major depressive episode with any regulatory approved antidepressant(s) at a minimally effective or higher dose for ≥8 weeks with the same stable dose for ≥4 weeks prior to the MGH ATRQ assessment at Screening
* Detectable blood level of a prescribed SSRI/SNRI/augmentation AP during Screening
* If clinically appropriate, willing to discontinue antidepressant and augmentation medications ≥5 half-lives prior to Baseline. No antidepressants or augmentation medications are allowed to be taken any time within 14 days prior to Baseline.
* MADRS total score ≥28 at Screening and Baseline
* CGI-S score ≥4 (moderately ill or worse) for depression at Screening and Baseline
* QIDS-SR16 score ≥16 at Screening and Baseline
* On all dosing days, participants must:

* Remain at the clinical site at least 4 hours postdose.
* Be accompanied upon discharge.
* Not to drive or operate heavy machinery for 24 hours postdose.

Exclusion Criteria

* Diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder, and persistent depressive disorder
* Substance use disorders within the last 6 months prior to Screening (excluding caffeine or nicotine)
* Evidence of delirium or unstable medical conditions (e.g., neurological, cardiovascular, cancer)
* Suicidal at Screening or Baseline defined as:

* "Yes" to C-SSRS questions 4 or 5 (current or over the last 6 months); OR
* Attempted suicide within 1 year prior to Visit 1 (Screening); OR
* Actively suicidal in the Investigator's judgment
* History of schizophrenia, psychotic disorders, MDD with psychotic features, bipolar I or II
* Being treated or require treatment for PTSD, acute stress disorder, panic disorder, or OCD
* History of neuroleptic malignant syndrome or serotonin syndrome
* History of epilepsy (except single febrile seizure in infancy)
* History of non-response to ADT during the induction phase, including ketamine and/or esketamine or other oral antidepressants (≥2 but ≤5 different antidepressant drugs)
* Allergy or sensitivity to ketamine or esketamine
* History of myocardial infarction, unstable angina, acute coronary syndrome, or cerebrovascular accident
* History of uncontrolled hypertension or hypertensive crisis, congestive heart failure \> NYHA Class II , Grade II or greater angina pectoris (by Canadian Cardiovascular Society Angina Grading Scale), sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, syncope due to an arrhythmia, an implantable cardiac defibrillator, or severe symptomatic hypotension
* Personal or family history of long QT syndrome or sudden cardiac death
* Atrial fibrillation unless adequately anti-coagulated
* History of a positive hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV test
* One or more clinical laboratory test value(s) at Screening outside the limits specified below:

* Hemoglobin \<12 g/dL (men) or \<11 g/dL (women)
* AST or ALT \>2× ULN
* Total bilirubin \>25.7 μmol/L (1.5 mg/dL), unless Gilbert's syndrome is documented
* Serum creatinine \>2× ULN
* Creatine kinase \>1000 U/L
* Severe renal impairment at Screening (eGFR of 30 mL/min)
* History of recurrent urinary tract infections, urinary tract neoplasm or benign enlargement and urinary retention
* Hypothyroidism at Screening (unless TSH is abnormal and reflex free T4 is normal)
* Unstable diabetes or HbA1c \>8% at Screening
* Abnormal ECG results at Screening or Baseline
* Heart rate \<50 beats per minute, not explained by regular exercise or medication
* BMI \<18.5 or \>35 kg/m2 at Screening or unintentional weight loss (i.e., ≥7%) over past 6 months
* Positive urine drug test for an illicit drug or cannabis at Screening or positive urine drug dipstick test result at Baseline
* Received electroconvulsive therapy (at least 7 treatments), transcranial magnetic stimulation, vagal nerve stimulation, or deep brain stimulation in the current episode of depression
* Received new-onset psychotherapy or had a change in the intensity of psychotherapy within 8 weeks prior to Screening
* Participated in a noninterventional study or clinical trial within 30 days or 5 half-lives, whichever is longer, of Baseline
* Employee or family member of an employee of Acadia Pharmaceuticals Inc.
* Judged to be inappropriate for the study, including if the participant is a danger to self or others (e.g., occupations in mass transportation or operating heavy machinery)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No